Collagen remodelling in myocardia of patients with diabetes.

M Shimizu, K Umeda, N Sugihara, H Yoshio, H Ino, R Takeda, Y Okada, I Nakanishi

Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.

AIMS: To investigate collagen remodelling in the interstitium of the heart in patients with diabetes. METHODS: Immunohistochemical study of the biopsied myocardium using type specific anticollagen antibodies (I, III, IV, V, VI) was performed in 12 patients with non-insulin dependent diabetes mellitus and six non-diabetic patients. There was no history of hypertension or coronary artery stenosis in any of the patients. RESULTS: Noticeable accumulations of collagen types I, III, and VI in the myocardial interstitium were recognised in both groups, but little accumulation of types IV or V was found. Types I and III mainly stained in the perimysium and perivascular region, while type VI predominantly stained in the endomysium. There was no disease specific accumulation of collagen in diabetes mellitus. The percentage of total interstitial fibrosis in the myocardium was significantly higher in the diabetic group than in the control group (p < 0.05). Although the percentages of collagen types I and VI did not differ between the two groups, the percentage type of III was significantly higher in the diabetic group than in the controls (p < 0.01). CONCLUSIONS: Collagen remodelling mainly as a result of an increase in collagen type III in the perimysium and perivascular region, occurs in the hearts of patients with diabetes.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Westermann, D., Van Linthout, S., Dhayat, S., Dhayat, N., Escher, F., Bucker-Gartner, C., Spillmann, F., Noutsias, M., Riad, A., Schultheiss, H.-P., Tschope, C. (2007). Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy. Diabetes 56: 1834-1841 [Abstract] [Full Text]  
• Westermann, D., Rutschow, S., Jager, S., Linderer, A., Anker, S., Riad, A., Unger, T., Schultheiss, H.-P., Pauschinger, M., Tschope, C. (2007). Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy: The Role of Angiotensin Type 1 Receptor Antagonism. Diabetes 56: 641-646 [Abstract] [Full Text]  
• Brower, G. L., Gardner, J. D., Forman, M. F., Murray, D. B., Voloshenyuk, T., Levick, S. P., Janicki, J. S. (2006). The relationship between myocardial extracellular matrix remodeling and ventricular function.. Eur. J. Cardiothorac. Surg. 30: 604-610 [Abstract] [Full Text]  
• Alla, F., Kearney-Schwartz, A., Radauceanu, A., Dores, S. D., Dousset, B., Zannad, F. (2006). Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail 8: 147-153 [Abstract] [Full Text]  
• Asbun, J., Villarreal, F. J. (2006). The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic Cardiomyopathy. J Am Coll Cardiol 47: 693-700 [Abstract] [Full Text]  
• Fang, Z. Y., Prins, J. B., Marwick, T. H. (2004). Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications. Endocr. Rev. 25: 543-567 [Abstract] [Full Text]  
• TSCHOPE, C., WALTHER, T., KONIGER, J., SPILLMANN, F., WESTERMANN, D., ESCHER, F., PAUSCHINGER, M., PESQUERO, J. B., BADER, M., SCHULTHEISS, H.-P., NOUTSIAS, M. (2004). Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J. 18: 828-835 [Abstract] [Full Text]  
• Candido, R., Forbes, J. M., Thomas, M. C., Thallas, V., Dean, R. G., Burns, W. C., Tikellis, C., Ritchie, R. H., Twigg, S. M., Cooper, M. E., Burrell, L. M. (2003). A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes. Circ. Res. 92: 785-792 [Abstract] [Full Text]